RxDoctor Payments Data

Ronald Hofmann, MD

Nephrology · Grand Rapids, MINPI 1295701209

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by AstraZeneca at 59.0% of the total. Reporting peaked in 2019 at $6,653 and has fallen 98.8% since, to $78 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,171in general payments, 2019–2025

Across 74 payments — averaging $123.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Otsuka America Pharmaceutical, Inc.$3K
  • Akebia Therapeutics Inc$187
  • Veloxis Pharmaceuticals, Inc.$163
  • Amgen$130
  • Mallinckrodt Hospital Products Inc.$106
  • plus $355 from 11 others

What the payments were for

  • Consulting fees$2,80031%
  • Speaking & faculty fees$4,65051%
  • Travel & lodging$270%
  • Food & beverage$1,46216%
  • Education$2323%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,171 in reported general payments places this provider in the 90th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$62,282
Medicare patients
270
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$26,396
Tacrolimus64$12,521
Cinacalcet Hcl77$11,361
Valganciclovir Hcl38$7,031
Valsartan173$5,531
Mycophenolic AcidMycophenolate Sodium26$4,846
Mycophenolate Mofetil32$4,208
Carvedilol252$3,983
Potassium Citrate ErPotassium Citrate16$2,973
Clonidine34$2,841
Methenamine Hippurate54$2,517
Atorvastatin Calcium176$2,067
Pravastatin Sodium141$2,057
Prednisone209$1,593
Metoprolol Succinate70$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$5,413$26,39641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 325 nephrology providers in Michigan.

Other nephrology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →